Trials / Recruiting
RecruitingNCT04899687
Study of Dextromethorphan in OCD and Related Disorders
Fluoxetine/Dextromethorphan in Obsessive-Compulsive and Related Disorders: an Open-Label Crossover Pilot Study
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.
Detailed description
Obsessive compulsive disorder (OCD) and the related disorders body dysmorphic disorder (BDD), somatic symptom disorder (SSD) and illness anxiety disorder (IAD) are psychiatric conditions characterized by recurrent, intrusive thoughts, feelings or images (obsessions or preoccupations) and repetitive or ritualized behaviors or avoidance performed to relieve obsession or preoccupation-related anxiety. They are a significant cause of mental health-related disability, and are inadequately served by available treatments. This study tests whether an over-the-counter cough suppressant medicine, dextromethorphan, may offer symptom relief when combined with a low dose of fluoxetine, a standard prescription treatment for OCD and related disorders.
Conditions
- Obsessive-Compulsive Disorder
- Illness Anxiety Disorder
- Body Dysmorphic Disorders
- Somatic Symptom Disorder
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluoxetine | Fluoxetine 20mg (or previously prescribed dose) will be taken once daily by mouth for 8 weeks |
| DRUG | Dextromethorphan | Dextromethorphan, an over-the-counter cough suppressant, will be taken by mouth twice daily for four weeks of the study, starting at 15mg per dose, and increasing weekly as tolerated to a maximum of 60mg per dose. |
Timeline
- Start date
- 2022-01-20
- Primary completion
- 2026-04-01
- Completion
- 2026-12-01
- First posted
- 2021-05-24
- Last updated
- 2025-08-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04899687. Inclusion in this directory is not an endorsement.